Having trouble accessing articles? Reset your cache.

Emerging Companies

Pneumagen: out-competing viral sugar binding to prevent infection

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...

Serentrix: pain relief without side effects

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...

Ohana: Looking to the other half of reproductive biology

The latest newco to be unveiled by Flagship Pioneering, Ohana, is homing in on the unexplored side of reproductive science with its sperm biology platform designed to address reproductive health issues ranging from fertility to...

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...

Relay’s protein motion platform approaches clinical starting line

With its first program due to enter the clinic this year, Relay will test its hypothesis that characterizing full-length protein targets across a range of conformations leads to better therapeutic candidates than conventional structure-based drug...

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is...

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

Alexis Borisy has launched EQRx to disrupt the biopharma world by developing and launching innovative therapies at “radically lower” prices than commercial competitors. With its first drug expected to hit the market in five years,...

NorthSea: Engineering fatty acids for NASH

With its structurally engineered fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea thinks it can succeed in the hepatic and cardiometabolic disease space where so many others...

Empirica: Building a new model for brain cancer

Empirica is developing antibody-based therapies for glioblastoma multiforme using a mouse model built to mimic the biology of recurrent brain cancer, rather than that of primary tumors. Its lead candidate is a CAR T cell...

Rheos: applying immune cell reprogramming to autoimmunity

As immune cell reprogramming is gaining traction in immuno-oncology, Rheos is applying the concept to autoimmune diseases with a platform that can pinpoint metabolic targets in immune cells to control their phenotype and function. The...

Click: personalized digital therapeutics for cognitive, neurobehavioral disorders

Click is developing a pipeline of personalized prescription digital therapeutics that could be used alone or in combination with traditional therapeutics to treat cognitive and neurobehavioral disorders. Launched in 2012, Click Therapeutics Inc. markets a...

Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

Centaurus is aiming for first-in-class small molecules that block the lipotoxicity driving cardiometabolic diseases. Stress stimuli such as inflammation increase production of the structural lipid ceramide, which induces apoptosis, necroptosis and cellular metabolism defects. Centaurus...